Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis.

Cryptogenic cirrhosis is a common cause of liver-related morbidity and mortality in the United States. Nonalcoholic fatty liver disease (NAFLD) is now recognized as the most common cause of cryptogenic cirrhosis. However, the diagnosis of cirrhosis in patients with NAFLD appears to be delayed compared with those with other chronic liver diseases and thus carries a higher mortality rate. This delay in diagnosis is illustrated in our case of a 53-year-old man who presented with hepatic hydrothorax and ascites, whose workup revealed cirrhosis due to NAFLD. Although a diagnosis of presumed NAFLD can be made noninvasively, a definitive diagnosis requires a liver biopsy specimen. A biopsy specimen is also important for detecting histologically advanced disease, which may be clinically silent and undetected by aminotransferases or diagnostic imaging. Although there are no proven treatments, recommendations for patients with NAFLD include avoidance of hepatotoxins and aggressive management of associated conditions, such as hypertriglyceridemia and type 2 diabetes mellitus.

[1]  J. Galambos,et al.  Natural history of alcoholic hepatitis. II. The long-term prognosis. , 1971, The American journal of gastroenterology.

[2]  H. Nomura,et al.  Prevalence of fatty liver in a general population of Okinawa, Japan. , 1988, Japanese journal of medicine.

[3]  F. Schaffner,et al.  Effect of weight reduction on hepatic abnormalities in overweight patients. , 1990, Gastroenterology.

[4]  R. Hanson,et al.  The natural history of nonalcoholic steatohepatitis: A follow‐up study of forty‐two patients for up to 21 years , 1990, Hepatology.

[5]  C. Gluud,et al.  Hepatic effects of dietary weight loss in morbidly obese subjects. , 1991, Journal of hepatology.

[6]  C. Tiribelli,et al.  Prevalence of chronic liver disease in the general population of northern Italy: The dionysos study , 1994, Hepatology.

[7]  M. Bennett,et al.  The natural history of nonalcoholic fatty liver: A follow‐up study , 1995, Hepatology.

[8]  G. Gores,et al.  Ursodeoxycholic acid or clofibrate in the treatment of non‐alcohol‐induced steatohepatitis: A pilot study , 1996, Hepatology.

[9]  L Dalla Palma,et al.  Noninvasive in vivo quantitative assessment of fat content in human liver. , 1997, Journal of hepatology.

[10]  K. Tanikawa,et al.  Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. , 1997, Journal of hepatology.

[11]  D. Sautereau,et al.  Dual-energy CT in the diagnosis and quantification of fatty liver: limited clinical value in comparison to ultrasound scan and single-energy CT, with special reference to iron overload. , 1998, Journal of hepatology.

[12]  F. Schick,et al.  Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. , 1999, American journal of physiology. Endocrinology and metabolism.

[13]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[14]  S. Caldwell,et al.  Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease , 1999, Hepatology.

[15]  M. Başaranoǧlu,et al.  A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. , 1999, Journal of hepatology.

[16]  K. Batts,et al.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis , 1999, Hepatology.

[17]  P. Thuluvath,et al.  Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case‐control study , 2000, Hepatology.

[18]  P. Giral,et al.  Liver fibrosis in overweight patients. , 2000, Gastroenterology.

[19]  J. Lavine Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. , 2000, The Journal of pediatrics.

[20]  M. Graif,et al.  Quantitative estimation of attenuation in ultrasound video images: correlation with histology in diffuse liver disease. , 2000, Investigative radiology.

[21]  Marco Zoli,et al.  Metformin in non-alcoholic steatohepatitis , 2001, The Lancet.

[22]  M. Gambardella,et al.  Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity , 2001, Hepatology.

[23]  K. Lindor,et al.  Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study , 2001 .

[24]  P. D. James,et al.  Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. , 2001, Journal of hepatology.

[25]  E. Brunt Nonalcoholic Steatohepatitis: Definition and Pathology , 2001, Seminars in liver disease.

[26]  F Vinicor,et al.  The continuing epidemics of obesity and diabetes in the United States. , 2001, JAMA.

[27]  F. Brancati,et al.  Nonalcoholic fatty liver disease: The most common cause of abnormal liver enzymes in the U.S. population , 2001 .

[28]  K. Lindor,et al.  Treatment of Nonalcoholic Fatty Liver: Present and Emerging Therapies , 2001, Seminars in liver disease.

[29]  P. Giral,et al.  Survival, liver failure, and hepatocellular carcinoma in obesity‐related cryptogenic cirrhosis , 2002, Hepatology.

[30]  D. Kotler,et al.  Liver Pathology in Morbidly Obese Patients Undergoing Roux-en-Y Gastric Bypass Surgery , 2002, Obesity surgery.

[31]  K. Flegal,et al.  Prevalence and trends in obesity among US adults, 1999-2000. , 2002, JAMA.

[32]  G. Loss,et al.  Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? , 2002, Hepatology.

[33]  F. Brancati,et al.  The prevalence and etiology of elevated aminotransferase levels in the United States , 2003, American Journal of Gastroenterology.

[34]  C. Degott,et al.  Fasting in obesity , 1982, Digestive Diseases and Sciences.